Shots:
Merz Therapeutics has enrolled the first patients in two global P-III studies, MINT-E (episodic migraine, ~990 pts) and MINT-C (chronic migraine, ~780 pts), evaluating the efficacy and safety of Xeomin (incobotulinumtoxinA) for migraine prevention
Both studies will recruit ~1,770 adults across 120 sites in North America & Europe, and recruitment in Europe is expected…
